

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA selpercatinib for treating advanced thyroid cancer
with RET alterations**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Currently, access to RET alteration testing is not uniform across the country, but is expected to be managed in specialist centres within the next year.

In the draft scope, the population age categories for RET-fusion positive thyroid cancer and RET-mutation positive medullary thyroid cancer were different (matching the eventual participants they had in their trials). However, there are barriers to access (and extremely limited treatment options) for people under the age of 18 who have these types of thyroid cancer. Clinical and patient experts at the scoping workshop raised the potential for both of the indications to incorporate people under the age of 18, not just one of them, as regulators might utilise safety data from paediatric patients from one of the indications in the trial, and apply it for other paediatric indications.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Committee should seek information from clinical and commissioning experts on whether changes to testing practices that were proposed/ongoing at the time of scoping have been implemented within the NHS by the time of decision-making for this topic.

Committee can only make recommendations within the marketing authorisation. This may include children and young people, depending on the marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes – population for both indications has been changed to ‘people’ rather than specifying age group or ‘adults’. This reflects groups which may be included in the anticipated marketing authorisation.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Jasdeep Hayre

Date: 03 August 2020